Abstract: FR-PO0469
Eligibility of ANZDATA Registry Patients for the CONVINCE Randomized Trial
Session Information
- Dialysis: Hemodiafiltration, Ultrafiltration, Profiling, and Interdialytic Symptoms
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Chua, Su Jen, Mercy Hospital for Women, Heidelberg, Victoria, Australia
- Brown, Leanne, Griffith University, Brisbane, Queensland, Australia
- Kairaitis, Lukas K., Blacktown & Mount Druitt Hospital, Blacktown, New South Wales, Australia
- Krishnasamy, Rathika, Sunshine Coast Hospital and Health Service, Nambour, Queensland, Australia
- See, Emily, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
- Semple, David, Te Whatu Ora Health New Zealand Te Toka Tumai Auckland, Auckland, New Zealand
- Toussaint, Nigel David, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
- Viecelli, Andrea K., Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Polkinghorne, Kevan, Monash University, Melbourne, Victoria, Australia
- Roberts, Matthew A., Eastern Health, Box Hill, Victoria, Australia
Group or Team Name
- ANZDATA Haemodialysis Working Group.
Background
The CONVINCE randomized trial demonstrated reduced all-cause mortality in patients undergoing hemodiafiltration (HDF) compared to high-flux hemodialysis (HD). Given the CONVINCE trial included participants likely to achieve >23L convection volume in post-dilution mode, we aimed to determine what proportion of patients in the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Registry could have been included.
Methods
We used ANZDATA Registry data from 2019-2023 to determine what proportion of adult hemodialysis patients were likely to achieve>23L convection volume and met the other eligibility criteria for the CONVINCE trial: 1) thrice weekly treatment, 2) blood flow >300mL/min, 3) no living donor kidney transplant anticipated within 6 months, 4) life expectancy >3 months.
Results
Of 21,264 patients receiving HD/HDF in Australia and New Zealand from 2019-2023, 6557 (30.8%) would have been eligible for the CONVINCE Study. Reasons for ineligibility were: <thrice weekly treatment (n=2061), blood flow ≤300mL/min (n=7315), living donor kidney transplant within 6 months (n=557), life expectancy <3 months (n=4193). Eligible participants were more likely to commence dialysis with native arteriovenous fistula (52% vs 39%, p<0.001). There was no difference in age, mortality and comorbidities in eligible versus ineligible participants.
Conclusion
Using real-world data, our analysis suggests that the CONVINCE trial findings could only be applied to one-third of patients undergoing HD/HDF in Australia and New Zealand. The major reason for exclusion was insufficient blood flow rate.
Table 1: Characteristics for patients eligible for CONVINCE versus not eligible
| Patient characteristics | CONVINCE Ineligible (n=14707) | CONVINCE Eligible (n=6557) | t-test | |
| Center characteristics at entry (%) | Major city Regional Remote | 9304 (77.8) 2338 (19.6) 310 (2.6) | 4384 (79.8) 866 (15.8) 241 (4.4) | <0.001 |
| Gender (%) | Female Intersex Male | 5949 (40.5) 0 (0.0) 8758 (59.5) | 2335 (35.6) 1 (0.0) 4221 (64.4) | <0.001 |
| Cause of ESKD (%) | Diabetic kidney disease Familial kidney diseases Glomerular disease Hypertension Tubulointerstitial disease Other | 6317 (43.5) 890 (6.1) 2564 (17.7) 1697 (11.7) 1194 (8.2) 1859 (12.6) | 2814 (43.3) 448 (6.9) 1244 (19.1) 760 (11.7) 491 (7.6) 746 (11.4) | 0.001 |
| Smoking status (%) | Current Former Never | 2006 (13.9) 5245 (36.4) 7152 (49.6) | 815 (12.7) 2329 (36.3) 3259 (50.8) | 0.049 |
| Age (mean (SD)) | 61.29 (14.73) | 61.40 (14.46) | 0.604 | |
| Diabetes status (%) | No diabetes Type 1 Type 2 - Insulin Type 2 - No Insulin | 6123 (42.0) 650 (4.5) 3860 (26.5) 3939 (27.0) | 2742 (42.0) 262 (4.0) 1727 (26.4) 1803 (27.6) | 0.448 |
| Dialysis vintage (days) (mean (SD)) | 634.38 (1251.15) | 885.77 (1392.81) | <0.001 | |
| Vascular access (%) | Native Non Tunnel CV Catheter Synthetic Tunnel CV Catheter | 5438 (39.3) 1230 (8.9) 159 (1.1) 7010 (50.7) | 2952 (51.6) 383 (6.7) 70 (1.2) 2313 (40.5) | <0.001 |
| Cause of death (%) | Cancer Cardiovascular Infection Not reported Other Withdrawal | 124 (3.0) 1829 (44.5) 502 (12.2) 211 (5.1) 1035 (25.2) 412 (10.0) | 69 (3.3) 907 (42.9) 253 (12.0) 86 (4.1) 564 (26.7) 237 (11.2) | 0.181 |
Keywords: CV = central venous; ESKD = end stage kidney disease